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Decreased oxygen availability in the kidney triggers theperitubular capillary lining cells within the kidney toproduce erythropoietin— the principal regulator of red
blood cell mass.1 Impaired oxygen delivery to the kidney can
result from various pathophysiologic mechanisms, such as ane-
mia, hypoperfusion due to renal arteriosclerosis, decreased renal
blood flow or heart failure, and decreased oxygen saturation due
to diseases such as chronic obstructive pulmonary  disease.1–5
Studies involving patients with chronic heart failure have
shown that high erythropoietin levels predict poor survival.6–11
However, whether this prognostic value is limited to patients
with heart failure or whether it is generalizable to very elderly
people regardless of specific pathologic conditions has not
been studied. We conducted this study to investigate whether
high levels of erythropoietin predict mortality among very
elderly people in the general  population.
Methods
Study population
The Leiden 85-plus Study is a population-based prospective
follow-up study involving 85-year-old inhabitants of Leiden,
the Netherlands. Between September 1997 and September
1999, 705 inhabitants of Leiden reached the age of 85 years
and were eligible for participation in the study. Fourteen people
died before enrolment; of the remaining 691, 92 refused to par-
ticipate, for a response rate of 86.7%.12 Of the 599 participants
enrolled in the study at age 85 years, 47 died before the age of
86, 39 refused further participation, and 16 refused blood sam-
pling. For six participants, their erythropoietin level could not
be measured because of technical problems. Erythropoietin lev-
els were available for 491 participants at age 86. Because ery-
thropoietin production is limited in patients with severe renal
failure, we excluded 44 participants who had severe renal fail-
ure (defined as a Cockcroft–Gault creatinine clearance of less
than 30 mL/min) and 19 for whom data on their creatinine
clearance were not available from the analyses. We included
the remaining 428 participants in our study. Participants were
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Background: The production of erythropoietin is triggered
by impaired oxygen delivery to the kidney, either because
of anemia or hypoxemia. High erythropoietin levels have
been shown to predict the risk of death among patients
with chronic heart failure. We investigated the prognostic
value of elevated erythropoietin levels on mortality among
very elderly people in the general population.
Methods: The Leiden 85-plus Study is a population-based
prospective follow-up study involving 599 people aged
85 years in Leiden, the Netherlands, enrolled between Sep-
tember 1997 and September 1999. Erythropoietin levels
were determined at age 86. For this analysis, we includ ed
428 participants with a creatinine clearance of at least
30 mL/min. Mortality data, recorded until Feb. 1, 2008,
were obtained from the municipal registry.
Results: During follow-up, 324 (75.7%) participants died.
Compared with participants whose erythropoietin levels were
in the lowest tertile (reference group), those whose levels
were in the middle tertile had a 25% increased risk of death
(hazard ratio [HR] 1.25, 95% confidence interval [CI] 0.95–
1.64), and those whose levels were in the highest tertile had a
73% increased risk (HR 1.73, 95% CI 1.32–2.26) (p value for
trend < 0.01). The association between erythropoietin levels
and mortality remained largely unchanged after we adjusted
for sex, creatinine clearance, hemoglobin level, comorbidity,
smoking status and C- reactive protein level, and was similar
for deaths from cardiovascular and noncardiovascular causes.
Interpretation: Among people aged 85 years and older,
elevat ed erythropoietin levels were associated with an in -
creased risk of death, independent of hemoglobin levels.
Abstract
@@     See related commentary by Glei and Weinstein, page 1943
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the assessment of functional tests and the collection of a venous
blood sample. All participants gave their informed consent.
The Medical Ethical Committee of Leiden University
Medical Center approved the study.
Laboratory measurements
Nonfasting blood samples were drawn before 11 am, and
serum samples were stored at −80°C.
In 2008, serum erythropoietin levels were measured in one
batch with the use of an enzyme immunoassay (Immulite
2500, Siemens Medical Diagnostics, Tarrytown, USA; sensi-
tivity 1.2 IU/L, coefficient of variation < 6%). Hemoglobin,
creatinine and C-reactive protein levels were determined on
the day the blood sample was drawn. Hemoglobin levels were
measured with the use of a fully automated system (Sysmex
XE-2100, TOA Medical Electronics, Kobe, Japan).  Anemia
was defined according to criteria of the World Health Organi-
zation (hemoglobin level < 130 g/L for men and < 120 g/L for
women).13 The serum creatinine concentration was measured
according to the Jaffe method with the use of a fully auto-
mated Hitachi 747 system (Hitachi, Tokyo, Japan). We esti-
mated creatinine clearances using the  Cockcroft–Gault for-
mula.14 The C-reactive protein level was used as a marker of
inflammation and was measured with the use of the Hitachi
747 automated analyzer (Hitachi, Tokyo, Japan).
Other clinical parameters
Information on the presence of disease (myocardial infarction in
medical history, stroke in medical history, heart failure, chronic
obstructive pulmonary disease, cancer, diabetes mellitus and
cognitive impairment) was obtained from general practitioners,
nursing-home physicians, pharmacy records and laboratory
findings.15 Diabetes mellitus was considered pres ent if diag-
nosed by the primary care physician, if the nonfasting glucose
level was greater than 11.0 mmol/L or if a participant was tak-
ing antidiabetic medication. The presence of severe cognitive
impairment was based either on a diagnosis by the general prac-
titioner or on a Mini-Mental State Examination score of less
than 19.16 Data on the use of angiotensin-converting-enzyme
inhibitors and angiotensin-receptor blockers at baseline were
obtained from pharmacy records. All of the participants were
interviewed about their current and former smoking habits.
Mortality data
Mortality data, recorded from the start of the study until Feb. 1,
2008, were obtained from the municipal registry. Causes of death
were obtained from Statistics Netherlands, where all national
death certificates are coded according to the International Classi-
fication of Diseases and Related Disorders, 10th revision. Causes
of death were divided into cardiovascular causes (codes I00–I99)
and noncardiovascular causes (all other codes).
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Table 1: Baseline characteristics of 428 participants at age 86 years, by tertile of erythropoietin level 
Tertile of erythropoietin level;* no (%) of participants† 
Characteristic 
Total 
n = 428 
Lowest 
n = 143 
Middle 
n = 143 
Highest 
n = 142 p value‡ 
Sex, male 142 (33.2) 46 (32.2) 45 (31.5) 51 (35.9) 0.50 
Erythropoietin, median (IQR), IU/L 10.4   (7.8–13.8) 7.2 (6.3–7.8) 10.4 (9.5–11.3) 15.7 (13.8–18.4)     – 
Hemoglobin, median (IQR), g/L 131 (123–139) 134 (128–142) 131 (125–138) 128 (120–136) < 0.01 
Anemia§   85 (19.9) 14 (9.8) 30 (21.0) 41 (28.9) < 0.01 
Creatinine clearance,** median (IQR), 
mL/min 
44.3 (38.9–51.8) 43.7 (38.5–50.5) 43.8 (38.1–53.1) 46.3 (39.6–52.7) 0.04 
C-reactive protein, median (IQR), mg/L 3 (0–7) 3 (0–5) 3 (0–7) 4 (1–7) < 0.01 
Cardiovascular disease†† 114 (26.6) 32 (22.4) 34 (23.8) 48 (33.8) 0.03 
Myocardial infarction   37   (8.6)   8   (5.6) 10   (7.0) 19 (13.4) 0.02 
Stroke   48 (11.2) 12   (8.4) 19 (13.3) 17 (12.0) 0.32 
Heart failure   54 (12.6) 17 (11.9) 10   (7.0) 27 (19.0) 0.07 
Chronic obstructive pulmonary disease   41 (9.6) 16 (11.2) 12 (8.4) 13   (9.2) 0.56 
Cancer   79 (18.5) 24 (16.8) 29 (20.3) 26 (18.3) 0.72 
Diabetes mellitus   61 (14.3) 16 (11.2) 19 (13.3) 26 (18.3) 0.09 
Severe cognitive impairment   87 (20.3) 28 (19.6) 34 (23.8) 25 (17.6) 0.68 
Former or current smoker 199 (46.5) 58 (40.6) 72 (50.3) 69 (48.6) 0.13 
Use of ACE inhibitors or angiotensin-
receptor blockers 
  59 (13.8) 17 (11.9) 15 (10.5) 27 (19.0) 0.08 
Note: ACE = angiotensin-converting enzyme, IQR = interquartile range. 
*Lowest tertile = 3.4–8.6 IU/L, middle tertile = 8.7–12.3 IU/L, highest tertile = 12.4–103.0 IU/L. 
†Unless stated otherwise. 
‡p values were obtained by the χ2 test (linear-linear, 1 degree of freedom) for categorical variables and the Jonkheere–Terpstra test for continuous variables. 
§World Health Organization criteria: hemoglobin level < 130 g/L for men and hemoglobin level < 120 g/L for women. 
**Determined using the Cockcroft–Gault formula. 
††Includes stroke, myocardial infarction and heart failure. 
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Statistical analysis
Participants were grouped according to the tertile of erythro-
poietin level: low (3.4–8.6 IU/L), middle (8.7–12.3 IU/L) and
high (12.4–103.0 IU/L). Differences in characteristics between
participants in the three tertiles were tested with the χ2 test (lin-
ear-linear, one degree of freedom) for categorical variables
and the Jonkheere–Terpstra test for continuous variables.
To investigate the association between erythropoietin level
and risk of death, we used Kaplan–Meier plots and Cox pro-
portional hazard models. The Kaplan–Meier plots were trun-
cated at eight years of follow-up because of small numbers at
the end of follow-up.
We constructed seven subsequent Cox proportional hazard
models, each model an extension of the previous one. In the first
model, we estimated the crude effect of erythropoietin level on
mortality. The second model was an extension of the first by
adjusting for sex. In subsequent models, we added creatinine
clearance (model 3), hemoglobin level (model 4), the presence
of disease (myocardial infarction, stroke, heart failure, chronic
obstructive pulmonary disease, cancer, diabetes mellitus and
severe cognitive impairment; model 5), smoking status (model
6) and C-reactive protein level (model 7). Erythropoietin tertile,
myocardial infarction, stroke, heart failure, chronic obstructive
pulmonary disease, cancer, diabetes, severe cognitive impair-
ment and smoking status were entered as categorical variables;
creatinine clearance, hemoglobin level and C-reactive protein
level were entered as continuous variables. To obtain a p value
for trend, we included the variable for erythropoietin tertile in
the model as a continuous variable.
Additional analyses were performed according to whether
participants had anemia at the age of 86. In these analyses,
participants with and without anemia were classified accord-
ing to strata-specific erythropoietin tertiles.
Results
The characteristics of the 428 participants at age 86 years are
summarized in Table 1. In brief, 33.2% of the study popula-
tion was male. The median erythropoietin level was
10.4 (interquartile range [IQR] 7.8–13.8, range 3.4–103.0)
IU/L. Anemia was present in 85 participants (19.9%), cardio-
vascular disease in 114 (26.6%) and chronic obstructive pul-
monary disease in 41 (9.6%). Participants in the highest ery-
thropoietin tertile had lower hemoglobin levels and higher
creatinine clearance and C-reactive protein levels than partici-
pants in the middle and lowest tertiles. The prevalence of ane-
mia and cardiovascular disease was highest among partici-
pants in the highest erythropoietin tertile.
During follow-up, 324 (75.7%) participants died: 98
(68.5%) in the lowest erythropoietin tertile, 108 (75.5%) in the
middle tertile and 118 (83.1%) in the highest tertile. Causes of
death were available for 319 participants: 115 (36.1%) died of
cardiovascular causes and 204 (63.9%) of noncardiovascular
causes. Participants in the highest erythropoietin tertile had the
highest all-cause mortality risk (Figure 1, log-rank test [2
degrees of freedom], p < 0.01). When compared with partici-
pants in the lowest erythropoietin tertile (reference group),
those in the middle tertile had a hazard ratio (HR) for death of
1.25 (95% confidence interval [CI] 0.95–1.64) and those in the
highest tertile an HR of 1.73 (95% CI 1.32–2.26) (p for trend
< 0.01, Table 2). These results did not change after we adjusted
the analysis for sex, creatinine clearance, hemoglobin level,
comorbidity, smoking status and C-reactive protein level (mid-
dle tertile, adjusted HR 1.07, 95% CI 0.80–1.44; highest tertile,
adjusted HR 1.69, 95% CI 1.26–2.26; p for trend < 0.01). Simi-
lar results were obtained when we excluded participants who
died during the first year of follow-up (middle tertile, adjusted
HR 1.13, 95% CI 0.83–1.55; highest tertile, adjusted HR 1.76,
95% CI 1.30–2.39; p for trend < 0.01) or when we excluded
participants who were using angiotensin- converting-enzyme
inhibitors and angiotensin-receptor blockers (middle tertile,
adjusted HR 1.06, 95% CI 0.77–1.46; highest tertile, adjusted
HR 1.72, 95% CI 1.24–2.39; p for trend < 0.01).
Figure 2 shows all-cause and cause-specific mortality from
age 86 onward by baseline erythropoietin tertile, adjusted for
sex, creatinine clearance, hemoglobin level, comorbidity,
smoking status and C-reactive protein level. The association
between erythropoietin and mortality was similar for deaths
from cardiovascular causes (middle tertile, adjusted HR 1.24,
95% CI 0.75–2.04; highest tertile, adjusted HR 1.79, 95% CI
1.09–2.92; p for trend = 0.02) and for deaths from noncardio-
vascular causes (middle tertile, adjusted HR 0.96, 95% CI
0.66–1.39; highest tertile, adjusted HR 1.58, 95% CI 1.09–
2.29; p for trend = 0.02).
Overall, 57 participants died of cancer: 15 (10.5%) in the
lowest erythropoietin tertile, 18 (12.6%) in the middle tertile
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Figure 1: Cumulative all-cause mortality among 428 participants
aged 86 at baseline, by tertile of erythropoietin level at baseline
(lowest = 3.4–8.6 IU/L, middle = 8.7–12.3 IU/L, highest = 12.4–
103.0 IU/L).
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and 24 (16.9%) in the highest tertile. When compared with
participants in the lowest tertile, those in the middle tertile
had an adjusted HR for death from cancer of 0.92 (95% CI
0.44–1.93) and those in the highest tertile had an adjusted HR
of 1.84 (95% CI 0.88–3.85) (p for trend = 0.10).
The results of the stratified Cox proportional hazard models
by presence or absence of anemia are presented in Table 3. In
both groups, higher baseline erythropoietin levels were associ-
ated with an increased risk of death from all causes. Among
participants without anemia (n = 343), high erythropoietin lev-
els remained associated with an increased risk of death from
all causes after adjustment for sex, creatinine clearance, hemo-
globin level, comorbidity, smoking status and C-reactive pro-
tein level (middle erythropoietin tertile, adjusted HR 1.19,
95% CI 0.86–1.67; highest tertile, adjusted HR 1.52, 95% CI
1.09–2.11; p for trend = 0.01). Among participants who had
anemia (n = 85), similar HRs were found after adjustment for
sex, creatinine clearance, hemoglobin level, comorbidity,
smoking status and C-reactive protein level; however, the
trend was no longer statistically significant (middle tertile,
adjusted HR 1.16, 95% CI 0.61–2.22; highest tertile, adjusted
HR 1.84, 95% CI 0.73–4.61; p for trend = 0.24).
Interpretation
In this population-based sample of very elderly people, we
found that high erythropoietin levels were associated with
increased risk of death, independent of creatinine clearance,
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Table 2: Risk of all-cause mortality among participants, by tertile of erythropoietin level at baseline 
Tertile of erythropoietin level;* HR† (95% CI) 
Model Adjustments‡ 
Lowest (ref)  
n = 143 
Middle 
n = 143 
Highest 
n = 142 
p value 
for trend 
1 None 1.00 1.25 (0.95–1.64) 1.73 (1.32–2.26) < 0.01 
2 + sex 1.00 1.26 (0.95–1.65) 1.75 (1.33–2.29) < 0.01 
3 + creatinine clearance 1.00 1.27 (0.96–1.67) 1.77 (1.35–2.32) < 0.01 
4 + hemoglobin 1.00 1.19 (0.90–1.58) 1.63 (1.23–2.15) < 0.01 
5 + comorbidity§ 1.00 1.11 (0.83–1.48) 1.69 (1.26–2.26) < 0.01 
6 + smoking 1.00 1.07 (0.80–1.44) 1.70 (1.27–2.28) < 0.01 
7 + C-reactive protein 1.00 1.07 (0.80–1.44) 1.69 (1.26–2.26) < 0.01 
Note: CI = confidence interval, HR = hazard ratio, ref = reference group. 
*Lowest tertile = 3.4–8.6 IU/L, middle tertile = 8.7–12.3 IU/L, highest tertile = 12.4–103.0 IU/L. 
†HRs were estimated using Cox proportional hazard models. 
‡Seven subsequent Cox proportional hazard models were performed, each an extension of the previous model. 
§Includes myocardial infarction, stroke, heart failure, chronic obstructive pulmonary disease, cancer, diabetes mellitus and severe cognitive impairment. 
Table 3: Risk of death among participants, by tertile of erythropoietin level and anemia status at baseline 
  Tertile of erythropoietin level* 




n = 114 
Middle tertile 
n = 115 
Highest tertile 





n = 29 
Middle tertile 
n = 28 
Highest tertile 
n = 28 
p value 
for trend 
1 None 1.00 1.40 (1.03–1.91) 1.55 (1.14–2.11) < 0.01 1.00 1.27 (0.71–2.28) 2.03 (1.16–3.56) 0.02 
2 + sex 1.00 1.42 (1.05–1.94) 1.61 (1.18–2.19) < 0.01 1.00 1.15 (0.64–2.10) 1.91 (1.08–3.36) 0.03 
3 + creatinine 
clearance 
1.00 1.44 (1.06–1.97) 1.62 (1.19–2.22) < 0.01 1.00 1.19 (0.66–2.16) 2.05 (1.15–3.65) 0.02 
4 + hemoglobin 1.00 1.42 (1.04–1.94) 1.60 (1.17–2.19) < 0.01 1.00 1.19 (0.65–2.17) 1.62 (0.84–3.15) 0.16 
5 + comorbidity** 1.00 1.24 (0.89–1.72) 1.51 (1.09–2.10) 0.01 1.00 1.09 (0.58–2.08) 1.80 (0.77–4.22) 0.23 
6 + smoking 1.00 1.20 (0.86–1.67) 1.52 (1.09–2.10) 0.01 1.00 1.16 (0.60–2.22) 1.98 (0.79–4.93) 0.19 
7 + C-reactive 
protein 
1.00 1.19 (0.86–1.67) 1.52 (1.09–2.11) 0.01 1.00 1.16 (0.61–2.22) 1.84 (0.73–4.61) 0.24 
Note: CI = confidence interval, HR = hazard ratio, ref = reference group. 
*For participants without anemia: lowest tertile = 3.4–8.2 IU/L, middle tertile = 8.3–11.7 IU/L, highest tertile = 11.8–30.5 IU/L. For participants with anemia: lowest 
tertile = 5.7–10.6 IU/L, middle tertile = 10.7–14.8 IU/L, highest tertile = 15.0–103.0 IU/L. 
†Hazard ratios were estimated using Cox proportional hazard models. 
‡World Health Organization criteria: hemoglobin level < 130 g/L for men and < 120 g/L for women. 
§Seven subsequent Cox proportional hazard models were performed, each an extension of the previous model. 
**Includes myocardial infarction, stroke, heart failure, chronic obstructive pulmonary disease, cancer, diabetes mellitus and severe cognitive impairment. 
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hemoglobin level, presence of comorbidities,
smoking status and circulating markers of
inflammation. The association between erythro-
poietin and mortality was similar for deaths from
cardiovascular causes and deaths from noncar-
diovascular causes.
Our results build on evidence from  stud ies
involving patients with chronic heart failure.6−11
A number of potential physiologic mechanisms
may underlie the association between elevated
erythropoietin and increased mortality indepen-
dent of hemoglobin level. The erythropoietin
level may be a biomarker of general hypoxia.
Patients with sleep apnea syndrome have been
found to have high erythropoietin levels, which
usually return to normal after effective continu-
ous positive airway pressure therapy.17 The ery-
thropoietin level is also increased after acute
myocardial infarction and is thought to protect
against the adverse effects of ischemia and hy -
poxia through reduction of the infarct size, in -
hibition of apoptosis and promotion of new ves-
sel formation.18 Elevated erythropoietin levels
could thus be a physiologic response to a chroni-
cally increased hypoxic stimulus due to yet undi-
agnosed (subclinical) disease.19,20 In addition, ele-
vated erythropoietin levels may be compensating
for removal of erythrocytes from the blood,
either because of hemolysis or blood loss.19,20
Each of these hypotheses should prompt clini-
cians to examine very elderly patients who have
elevated erythropoietin levels for underlying dis-
ease, especially if anemia is not present. Oxygen
saturation or arterial oxygen tension measure-
ments, unfortunately not available in our study,
may shed light on the mechanisms that are at
play and may help to identify the clinical and
therapeutic implications of elevated erythropoi-
etin levels in elderly patients. 
High erythropoietin levels may also be a reflection of
bone marrow resistance to endogenous erythropoietin
caused by bone marrow senescence or bone marrow exhaus-
tion, comparable to insulin resistance in type 2 diabetes mel-
litus.9,19,21,22 Over the past years, a number of un expected
 nonhematopoietic functions of erythropoietin have been
identified.23 Perhaps erythropoietin itself contributes to a
poor outcome because of its recently established prothrom-
botic platelet- activating or tumour- promoting effects.7,23,24
In our study, high erythropoietin levels were associated
with increased mortality, regardless of the presence of ane-
mia. However, among participants with anemia, the associa-
tion between erythropoietin and mortality was no longer sta-
tistically significant when hemoglobin levels were added into
the Cox proportional hazard model. Although this result could
have been due to the small number of participants with ane-
mia, it may also suggest that different mechanisms underlie
the associations between erythropoietin and mortality in very
elderly patients with and without anemia.
We do not know whether elevated erythropoietin, apart
from being a risk marker of increased mortality in very
elderly patients, is also a causal risk factor for increased mor-
tality. Our findings do not necessarily mean that very elderly
people with renal failure, cancer or unexplained anemia
should not be given recombinant erythropoietin. Such treat-
ment has been shown to be effective in raising hemoglobin
levels and improving the quality of life in patients with chro -
nic renal disease and cancer,25–28 and in community-dwelling
elderly patients with unexplained chronic anemia.29 In theory,
if bone marrow resistance is the primary explanation for our
findings, elevated erythropoietin levels may reflect a relative
erythropoietin deficiency and indicate the need for treatment
with recombinant erythropoietin. Still, recent meta-analyses
of randomized trials showed that treatment with erythro-
poiesis-stimulating agents in pa tients with chronic renal dis-
ease or cancer had a negative influence on survival,30–32 which
clearly emphasizes the need for further studies into the cause
and effects of high erythropoietin levels in elderly patients.
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All-cause mortality
Lowest tertile  n = 143
Middle tertile  n = 143
Highest tertile  n = 142
Cardiovascular mortality
Lowest tertile  n = 143
Middle tertile  n = 143
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Noncardiovascular mortality
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Middle tertile  n = 143
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Figure 2: All-cause and cause-specific mortality among 428 participants aged
86 at baseline, by tertile of erythropoietin level at baseline (lowest = 3.4–8.6
IU/L, middle = 8.7–12.3 IU/L, highest = 12.4–103.0 IU/L). Hazard ratios (HRs)
were adjusted for sex, creatinine clearance, hemoglobin level, comorbidity,
smoking status and C-reactive protein level. Values greater than 1.0 indicate
an increased risk of death.
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Limitations and strengths
Our study has several limitations. In our attempt to investigate
the independent effect of elevated erythropoietin levels on mor-
tality, we excluded participants with severe renal failure and
adjusted the Cox proportional hazard models for renal function,
hemoglobin level, comorbidity, smoking status and C-reactive
protein level. Since all of these factors may have a direct influ-
ence on the production of erythropoietin, we adjusted for fac-
tors in the causal pathway that may have led to an underestima-
tion of the true association between erythropoietin level and
mortality. Other limitations of the study are its observational
nature, which did not allow us to exclude the possibility of
residual confounding by the presence of disease, and the lack
of oxygen saturation or arterial oxygen measurements, which
inhibited us from further exploring underlying physiologic
mechanisms that could explain our findings. Another limitation
of our study is its relatively small sample, especially of partici-
pants with anemia, which led to insufficient power to study the
effect of erythropoietin on specific causes of death.
Our study has several strengths. The Leiden 85-plus Study is
a prospective population-based study with a high response rate
and complete nine-year follow-up data for mortality. Our sam-
ple reflects the general population of very elderly people and
includes people with and without comorbidities. Our results
were not affected by the use of recombinant erythropoietin treat-
ment, since none of the participants in our study used this type
of medication during the study period. In addition, instead of
using clinical cut-off points for erythropoietin, which are still
subject to debate, we used tertiles of erythropoietin levels, which
allowed us to investigate whether the association between ery-
thropoietin and mortality showed a biological gradient.
Conclusion
Elevated erythropoietin levels in very elderly people were
associated with an increased risk of death, independent of
hemoglobin level. Further studies are needed to explore the
underlying pathophysiologic mechanisms and to identify the
clinical relevance and therapeutic implications of elevated
erythropoietin levels in this age group.
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